Hypoxia imaging with [F-18] FMISO-PET in head and neck squamous cell carcinoma

1276

21st ICOMS 2013—Abstracts: Oral Papers

assay. Furthermore, target genes of TS-miRs were explored with the use of microarray and Ingenuity Pathway Analysis (IPA). We also investigated the expression levels of TS-miRs in OSCC and SGC tissues by real-time quantitative RT-PCR (qRT-PCR). Results: In comprehensive functional analysis using human synthetic mature miRNAs, miRNA-1289 (miR-1289) markedly inhibited the growth of both types of cells. The growth rate of GFPSAS and GFP-ACCM cells transfected with miR-1289 reduced by 86.4% and 50.7%, respectively. In microarray and IPA, the expression of 13 cancer-related genes including cyclin E1 was commonly down-regulated in human oral cancer cells by transfection with miR-1289. Furthermore, qRT-PCR revealed decreased expression of miR-1289 in 32 of 45 OSCC and 3 of 5 SGC tissues compared to normal oral mucosa and salivary gland tissues, respectively. Conclusions: These results suggest that miR-1289 functions as a novel TS-miR in human oral cancer cells, and may be a useful therapeutic tool for the patients with oral cancer. Key words: microRNA; oral cancer; tumor suppressor http://dx.doi.org/10.1016/j.ijom.2013.07.351 T18.OR016 Hypoxia imaging with [F-18] FMISO-PET in head and neck squamous cell carcinoma A. Iwasaki ∗ , Y. Ohbayashi, T. Miki, F. Sawai, M. Miyake, Y. Matsui Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan Tumor hypoxia adversely affects clinical radiation response of head and neck squamous cell carcinoma. 18F-fluoromisonidazole positron emission tomography ([F-18]FMISO-PET) offers a noninvasive means of assessing viable hypoxic tissue in tumor. We evaluate hypoxia imaging with [F-18]FMISO-PET in HNSCC treated with chemoradiotherapy. A total of 11 patients with HNSCC agreed to participate in this study. All of the patients underwent pretreatment [F-18]FMISO-PET. SUVmax and tumorto-muscle ratios(TMR) were measured as hypoxia indicators. 9 patients of them had primary tumor hypoxia. 2 of 10 patients with neck metastasis had nodal hypoxia. All patients were treated with chemoradiation therapy. As clinical response of chemoradiotherapy, 8 patients achieved CR, 3 patients achieved PR. Remain viable carcinoma cell of 3 PR cases existed in hypoxia region imaged with [F-18]FMISO-PET. The current result suggest that we could apply 18-F fluoromisonidazole positron emission tomography/computed tomography ([F-18]FMISO-PET/CT)-guided intensity-modulated radiotherapy(IMRT) in dose escalation to attack the hypoxic volume of a tumor mass without increasing the normal tissue dose in head and neck cancer patients in order to improve the clinical response. http://dx.doi.org/10.1016/j.ijom.2013.07.352

T18.OR017 Image-guided stereotactic radiotherapy combined with oral chemotherapy for patients with recurrent head and neck carcinoma – over 5-year follow-up study K. Kawaguchi 1,∗ , A. Horie 2 , H. Yamada 1 , Y. Goroku 1 , Y. Hamada 1 1

Tsurumi University School of Dental Medicine, Department of Oral & Maxillofacial Surgery, Japan 2 Toho University School of Medicine, Department of Oral & Maxillofacial Surgery, Japan Background and objectives: The aim of this study is to examine the effect of Image-guided stereotactic radiotherapy (IGSRT) in the treatment of advanced, recurrent lesions for head and neck carcinoma both with and without lymph node involvement. Methods: Between April 2006 and July 2007, 22 patients (mean age 67 years) with advanced, recurrent head and neck carcinoma were treated with IGSRT by CyberKnife-II. Patients included 3 rT2, 8 rT3, and 9 rT4; 8 of the patients had lymph node metastases. Marginal irradiated doses were 20–42 Gy delivered in two to five fractions. Starting one month after IGSRT, all patients received S-1 oral chemotherapy for one year. Treatment outcome was assessed based on the Response Evaluation Criteria in Solid Tumors, (RECIST) Version 1.1. Toxicities were graded using Common Terminology Criteria for Adverse Event (CTCAE) Version 4.03. Overall survival was determined by Kaplan–Meier survival analysis. Results: At an overall median follow-up of 67 months (range, 4–80 months), for the 14 locally recurrent patients without lymph node metastases, 9 patients (64.3%) had a complete response (CR), 1 patient (7.1%) had a partial response (PR), 1 patient (7.1%) had stable disease (SD), and 3 patients (21.4%) had progressive disease (PD). For the 8 patients with lymph node metastases, 1 patient with a single retropharyngeal (12.5%) had CR; the remaining 7 patients (87.5%) all progressed. Nine patients have died from their cancer. The overall 5-year survival for the patients with and without lymph node metastases was 12.5% and 78.6% (p = 0.0000019 by log-rank test). Three of the patients who had previously received external beam radiation experienced Grade 2 osteoradionecrosis for 10–18 months. Conclusions: These results show the benefit of local control by IGSRT using CyberKnife combined with S-1 Oral chemotherapy for advanced, recurrent lesions, without lymph node metastases in previously irradiated head and neck cancer. http://dx.doi.org/10.1016/j.ijom.2013.07.353 T18.OR018 Ectopic expression of fatty acid binding protein 4 is involved in cell growth of lingual squamous cell carcinoma D. Lee 1,∗ , K. Wada 2 , Y. Taniguchi 1 , M. Okura 1 , M. Kogo 1 1 The First Department of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Osaka University, Japan 2 Department of Pharmacology, Graduate School of Dentistry, Osaka University, Japan

Background and objectives: Fatty acid binding protein 4 (FABP4) is an intracellular lipid chaperone molecules that are expressed and involved in functions of adipocyte, macrophage, and dendritic cell. However, little is known about the expression and role of FABP4 on tumor cells, especially squamous cell car-